What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Asthma
His primary areas of investigation include COPD, Internal medicine, Immunology, Placebo and Anesthesia.
His work carried out in the field of COPD brings together such families of science as Respiratory disease, Exacerbation, Randomized controlled trial, Intensive care medicine and Physical therapy.
His Randomized controlled trial research is multidisciplinary, relying on both Inhaler and Beclometasone dipropionate.
Dave Singh studied Internal medicine and Gastroenterology that intersect with Systemic inflammation and Analysis of variance.
His Immunology study combines topics in areas such as Sputum, Lung and Pharmacology.
His Placebo research is multidisciplinary, incorporating elements of Area under the curve, Adverse effect, Methacholine, Aclidinium bromide and Asthma.
His most cited work include:
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary (1253 citations)
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 (472 citations)
- Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD (398 citations)
What are the main themes of his work throughout his whole career to date?
COPD, Internal medicine, Immunology, Asthma and Placebo are his primary areas of study.
Dave Singh has researched COPD in several fields, including Exacerbation, Sputum, Bronchodilator and Physical therapy.
His work on Gastroenterology expands to the thematically related Internal medicine.
His research in Immunology intersects with topics in Corticosteroid and Lung.
His Placebo study incorporates themes from Tolerability, Adverse effect, Anesthesia and Formoterol.
As part of the same scientific family, he usually focuses on Pulmonary disease, concentrating on Intensive care medicine and intersecting with Obstructive lung disease.
He most often published in these fields:
- COPD (61.24%)
- Internal medicine (42.64%)
- Immunology (28.22%)
What were the highlights of his more recent work (between 2019-2021)?
- COPD (61.24%)
- Internal medicine (42.64%)
- Exacerbation (15.50%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in COPD, Internal medicine, Exacerbation, Asthma and Intensive care medicine.
Dave Singh studies COPD, focusing on Obstructive lung disease in particular.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Placebo.
His Exacerbation research includes elements of Metered-dose inhaler, Copd exacerbation, Rate ratio, Beclometasone dipropionate and Hazard ratio.
Asthma is a primary field of his research addressed under Immunology.
While the research belongs to areas of Intensive care medicine, he spends his time largely on the problem of Clinical trial, intersecting his research to questions surrounding Randomized controlled trial.
Between 2019 and 2021, his most popular works were:
- Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. (104 citations)
- Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. (90 citations)
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD (48 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Asthma
Dave Singh focuses on COPD, Internal medicine, Pulmonary disease, Gastroenterology and Intensive care medicine.
He does research in COPD, focusing on Obstructive lung disease specifically.
His work in Internal medicine addresses issues such as Placebo, which are connected to fields such as Adverse effect and Clinical trial.
Dave Singh works mostly in the field of Pulmonary disease, limiting it down to topics relating to Corticosteroid and, in certain cases, Blood eosinophils.
His studies deal with areas such as Pharmacokinetics, Inhalation, Crossover study, Tolerability and Bronchial epithelium as well as Gastroenterology.
His Intensive care medicine research integrates issues from Disease progression, Disease, MEDLINE, ARDS and Severity of illness.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
